Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5041MR)

This product GTTS-WQ5041MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Heloderma suspectum
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5041MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8994MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ894MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ484MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ15881MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ2162MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ7134MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ10314MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ15818MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb14045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW